Enrollment

*Note: To ensure course material is received before the course begins, early registration is advised. Registration will close at 5:00 PM on Friday, September 24^th. Day-of enrollments will not be accepted.

Course Fees

• Practicing Physicians: $75.00
• UC-based medical school faculty and IDAC members: $60.00
• Fellows, Trainees and Others: $30.00*
  • * Includes all public health professionals

Enroll Online

To enroll click here.

By Phone

Call (310) 794-2620 and use your American Express, MasterCard, VISA or Discover card.

Refunds

Cancellations must be received in writing by Monday, August 30, 2021 and will be subject to a $25 processing fee. No refunds will be granted after that date. If, for any reason, the course must be cancelled, discontinued, or rescheduled by the Office of Continuing Medical Education, a full refund will be provided.

Course Chair

Claire Panosian Dunavan, MD, DTM&H (London)
Past-President, American Society of Tropical Medicine and Hygiene
Clinical Professor of Medicine and Infectious Diseases, Emeritus/Recalled
David Geffen School of Medicine at UCLA

Claire Panosian Dunavan is an infectious diseases specialist and clinical professor emeritus-recalled at UCLA School of Medicine who attended Stanford (A.B. History), Northwestern Medical School (M.D.) and the London School of Hygiene and Tropical Medicine, then trained in internal medicine and infectious diseases at Northwestern and Tufts-New England Medical Center.

In the 1980s, Panosian was Chief of Infectious Diseases at LA County-Olive View Medical Center, then moved to UCLA’s main medical campus to establish its first-ever Travel and Tropical Medicine Clinic, teach in the medical school and on UCLA’s main campus, work in developing countries as a clinical consultant, and collaborate on global health policy initiatives, including as an author/consultant for the National Academies of Medicine in Washington, DC. In 2005, she co-founded UCLA’s Program in Global Health; in 2008, she served as the President of the American Society of Tropical Medicine and Hygiene.

Claire Panosian Dunavan’s second career in media includes writing and on-camera/on-air reporting for national TV and radio. In 1999, she created “The Doctor Files” column for the L.A. Times. Her narrative non-fiction has also appeared in Discover, Scientific American, The New York Times, Washington Post, Baltimore Sun, Chicago Tribune, The Hill, The New England Journal of Medicine, JAMA, Health Affairs, and UCLA’s “U” magazine. She is currently writing a popular book about modern foodborne infections and has recently produced a documentary about a globalizing foodborne parasite currently present in Hawaii, the southern U.S. and other semi-tropical locales on five continents. “Accidental Host—The Story of Rat Lungworm Disease” will air in 2022. Dunavan is a member of the Writers Guild of America west.

Course Faculty

Mary Catherine Cambou, MD
Fellow, Division of Infectious Diseases
David Geffen School of Medicine at UCLA
PhD Student, UCLA Fielding School of Public Health

Dr. Cambou is a PGY-7 fellow in Adult Infectious Diseases at the David Geffen School of Medicine at UCLA, and a rising 3rd year PhD student at the Fielding School of Public Health. Her primary research interests lie at the intersection of women's health and infectious diseases, including infections in pregnancy. After graduating from UC Berkeley with a degree in Molecular and Cell Biology, Dr. Cambou worked in nutritional biochemistry epidemiology research for two years at UCLA. During medical school at the David Geffen School of Medicine at UCLA, she spent one year studying HIV and HPV co-infection in women in Rio de Janeiro, Brazil through the NIH-funded South American Program in HIV Prevention Research (SAPHIR). After completing her residency in social internal medicine at Montefiore in New York, she returned to UCLA for clinical training in Infectious Diseases and simultaneous work towards her PhD. Dr. Cambou is one of the site investigators for the COVID-19 in Mother-Infant Pairs (COMP) Study, a multi-site observational cohort designed to evaluate the long-term clinical outcomes and immunologic responses of COVID-19 infection in pregnancy. The COMP Study has recruited over 250 mother-infant dyads from Los Angeles and Rio de Janeiro. Dr. Cambou has authored over 15 publications, and recently co-authored a chapter on viral infections in pregnancy for the textbook Creasy & Resnik's Maternal-Fetal Medicine.

John Clemens, MD
Past Executive Director, International Centre for Diarrhoeal Disease Research, Bangladesh
Senior Scientific Advisor, International Vaccine Institute, Seoul, Korea

Dr. Clemens is an infectious disease epidemiologist with over 30 years of experience designing, conducting, and analyzing large, population-based epidemiologic studies and vaccine field trials in developing countries, including Tanzania, Mozambique, Bangladesh, Ghana, DRC, India, Pakistan, China, Indonesia, Vietnam, and Chile. His work on bacterial enteric pathogens has included studies on cholera, typhoid, shigellosis, and ETEC.

A graduate of Stanford (B.S.) and Yale (M.D.) Universities, Dr. Clemens trained in Internal Medicine at Case Western Reserve, and received his post-doctoral research training in clinical epidemiology at Yale. From 1983-88, he served as a research scientist at the International Centre for Diarrhoeal Disease Research, Bangladesh, where he led the first efficacy trial of an oral vaccine against cholera. After returning to the U.S., he served as Chief of the Epidemiology Section of the Center for Vaccine Development of the University of Maryland, and then as Chief of the Epidemiology Branch of the National Institute of Child Health and Human Development at NIH. While at NIH he was the Director of the first WHO Collaborating Centre for Vaccine Evaluation in Developing Countries. In 1999 he became the first Director-General of the International Vaccine Institute (IVI). While at IVI he led the team that developed a killed oral cholera vaccine that achieved licensure in India in 2009 and WHO prequalification in 2010. In 2011 he moved to UCLA, where he continues to serve as Adjunct Professor of Epidemiology. From 2013-21, Dr Clemens he was the Executive Director of the International Centre for Diarrheal Disease Research (icddr,b), and in May, 2021 he returned to the IVI, where he serves as Senior Scientific Advisor to the Director General.

Dr. Clemens is the author of over 450 peer-reviewed publications and was the recipient of the 2010 Sabin Gold Medal as well as the 2018 Prince Mahidol Prize in Public Health.

William D. Marler, Esq.
Marler Clark LLP PS
The Food Safety Law Firm

An accomplished attorney and national expert in food safety, William (Bill) Marler graduated from the Seattle University School of Law in 1987, and in 1998 served as the Law School’s “Lawyer in Residence.” He is now the most prominent foodborne illness lawyer in America and a major force in food policy in the U.S. and around the world. Marler Clark, The Food Safety Law Firm, has represented thousands of individuals in claims against food companies whose contaminated products have caused life altering injury and even death.

Marler began litigating foodborne illness cases in 1993, when he represented the most seriously injured survivor of the historic Jack in the Box E. coli O157:H7 outbreak in her landmark $15.6 million settlement with the company. The 2011 book, “Poisoned: The True Story of the Deadly E. coli Outbreak that Changed the Way Americans Eat” chronicles the outbreak and Bill Marler's rise as a food safety attorney. For the last 25 years, he has represented victims of nearly every large foodborne illness outbreak in the United States. He has filed lawsuits against such companies as Chili’s, Chi-Chi’s, Cargill, ConAgra, Dole, Excel, Golden Corral, KFC, McDonald’s, Odwalla, Peanut Corporation of America, Sheetz, Sizzler, Supervalu, Taco Bell and Wendy’s, securing over $600,000,000 for victims of E. coli.

Bill Marler’s advocacy for a safer food supply includes petitioning the United States Department of Agriculture to better regulate pathogenic E. coli, working with nonprofit food safety and foodborne illness victims’ organizations, and helping spur the passage of the 2010-2011 FDA Food Safety Modernization Act. He has addressed local, national, and international gatherings on food safety, including testimony before the U.S. House of Representatives Committee on Energy and Commerce. He is the publisher of the online news site, Food Safety News and an award-winning blog.

Stephen Ostroff, MD
Past Deputy/Acting Commissioner, U.S. Food and Drug Administration
Adjunct Professor, University of Pittsburgh School of Public Health
Adjunct Assistant Professor, Pennsylvania State College of Medicine

Dr. Stephen Ostroff served as the Deputy Commissioner for Foods and Veterinary Medicine at the Food and Drug Administration (FDA) until early 2019. In addition to that position, he also served as the agency’s Chief Scientist and on two occasions as the Acting FDA Commissioner.

Before joining the FDA, Dr. Ostroff worked at the Centers for Disease Control and Prevention (CDC) in Atlanta for more than two decades on infectious disease surveillance and outbreak investigations, especially management and coordination of complex emerging infections. He served as the Associate Director for Epidemiologic Science in the National Center for Infectious Diseases (NCID) and as NCID Deputy Director. He attained the rank of Assistant Surgeon General in the US Public Health Service Commissioned Corps. Between leaving CDC and joining FDA, Dr. Ostroff performed similar work at the Pennsylvania Department of Health directing the Bureau of Epidemiology and serving as Pennsylvania’s Acting Physician General.

Dr. Ostroff received his medical degree from the University of Pennsylvania School of Medicine and did residency training in internal medicine and preventive medicine. He holds adjunct faculty appointments at Penn State College of Medicine and the University of Pittsburgh Graduate School of Public Health.

David Pegues, MD
Professor of Medicine, Division of Infectious Diseases
Perelman School of Medicine, University of Pennsylvania

David Pegues, MD, is a Professor of Medicine in the Division of Infectious Diseases at the Perelman School of Medicine that the University of Pennsylvania. He serves as the Medical Director of Healthcare Epidemiology, Infection Prevention and Control and Associate Director of the Antimicrobial Stewardship Program at the Hospital of the University of Pennsylvania. Prior to coming to Penn, he attended medical school at the University of Chicago, trained at Temple University Hospital, CDC, and Massachusetts General Hospital and was on the faculty at the David Geffen School of Medicine at UCLA. His curent research interests include developing clinical decision support tools to improve testing stewardship and reduce inappropriate device utilization; evaluating novel technologies and implementation strategies to reduce environmental microbial contamination and infection risk; and the epidemiology and prevention of infections in solid organ transplant recipients. He has a longstanding interest in the epidemiology and management of enteric diseases, particularly salmonellosis, and co-authors chapters on Salmonella species in Harrison’s Principles of Internal Medicine and major infectious disease textbooks.

Duc J. Vugia, MD, MPH
Chief, Infectious Diseases Branch, California Dept of Public Health
Clinical Professor of Epidemiology and Biostatistics, UCSF

Dr. Duc Vugia received his MD from the University of California San Francisco (UCSF) and his MPH in Epidemiology from UC Berkeley. He was trained in Internal Medicine and Infectious Diseases before starting his public health career as an Epidemic Intelligence Service officer with the U.S. Centers for Disease Control and Prevention (CDC) in 1990 and then continuing with the California Department of Public Health (CDPH) in 1994. Since 1995, Dr. Vugia has been Chief of the Infectious Diseases Branch at CDPH where he worked with local, state, and federal partners to address foodborne, waterborne, vector-borne, zoonotic, and emerging infectious diseases. He has authored or coauthored over 200, over 60 of which are on foodborne diseases and outbreaks. In his presentation on foodborne botulism, Dr. Vugia will recount how his epidemiology staff worked with laboratory and local public and environmental health partners to solve an outbreak of foodborne botulism.

Mary E. Wilson, MD
Clinical Professor of Epidemiology and Biostatistics, UCSF
Adjunct Professor of Global Health and Population,
TH Chan School of Public Health, Harvard University

Mary E. Wilson, MD is Clinical Professor of Epidemiology and Biostatistics, University of California, San Francisco and Adjunct Professor of Global Health and Population, Harvard T.H. Chan School of Public Health. Her academic interests include antibiotic resistance, the ecology of infections and emergence of microbial threats, travel medicine, tuberculosis, and vaccines. She received an M.D. from the University of Wisconsin and completed an internal medicine residency and infectious diseases fellowship at Beth Israel Hospital in Boston. She is a fellow in the Infectious Diseases Society of America, the American College of Physicians, the American Society of Tropical Medicine and Hygiene, and the International Society of Travel Medicine. She has served on the Advisory Committee on Immunization Practices (ACIP) of the CDC, the Academic Advisory Committee for the National Institute of Public Health in Mexico, and on six committees for the National Academies of Sciences, Engineering, and Medicine, where she was Vice-Chair of the Forum on Microbial Threats through 2019 and is a member of the One Health Action Collaborative. She was a member of the Pew National Commission on Industrial Farm Animal Production, whose report, Putting Meat on the Table: Industrial Farm Animal Production in America, was released in 2008 and is author of Antibiotics: What Everyone Needs to Know (Oxford University Press, 2019). She served on the Board of Trustees for icddr,b in Bangladesh for 6 years, is a member of the Advisory Board for the Fogarty International Center at the National Institutes of Health, and is on the Board of Directors for the Center for Disease Dynamics, Economics, and Policy.

At the conclusion of this course, participants should be able to:

• Name 3 key features of the Food Safety Modernization Act of 2011
• Describe recent trends in the epidemiology of Salmonella, Campylobacter, norovirus and E. coli 0157:H7 and other Shiga-toxin producing E. coli (STECs)
• Diagnose and treat Salmonella, Campylobacter, norovirus and STEC infections
• Recognize acute and long-term consequences of foodborne infections
• Discuss the farm-to-fork movement of antimicrobial-resistant organisms in modern food chains
• Understand the transmission and consequences of infections due to Listeria and Toxoplasma contracted during pregnancy
• Describe the diverse vehicles, clinical manifestations and modern treatment of foodborne botulism
• Cite legal and corporate consequences of major foodborne outbreaks
• Update knowledge of cholera vaccines currently used in international outbreaks and high-risk travelers
• Recognize modern epidemiology and clinical features of several foodborne parasites (Cyclospora, Anisakis, Trichinella, Angiostrongylus, AKA “rat lungworm”) currently seen in the U.S.
• Counsel patients on specific strategies to avoid foodborne infections

The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits ^TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The California State Board of Registered Nursing accepts courses approved by the AMA for category 1 credit as meeting the continuing education requirements for license renewal. Nurses from states other than California should inquire with their local State Board for specific continuing education policies.

The FDA has issued a concept paper which classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is "truly independent" and free of commercial influence. In addition to independence, the FDA requires that nonpromotional, commercially supported education be objective, balanced, and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty be fully disclosed to the program's participants. In addition, Accreditation Council for Continuing Medical Education policy mandates that the provider adequately manages all identified potential conflicts of interest prior to the program. We at UCLA fully endorse the letter and spirit of these concepts.